Article information
Full text is only aviable in PDF
Bibliografía
[1.]
J.L. Carreras.
La tomografía por emisión de positrones en oncología.
Toravilla, (1995), pp. 1-117
[2.]
L.D. Lamki.
Positron emission tomography in oncology: general acceptance of its role is overdue.
Cancer, 78 (1996), pp. 2.039-2.042
[3.]
D.E. Midthun, S.J. Swensen, J.R. Pett.
Clinical strategies for solitary pulmonary nodules.
Ann Rev Med, 93 (1992), pp. 195-208
[4.]
N.A. Dewan, N.C. Gupta, L.S. Redeppenning, J. Phallen, M. Frick.
Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules.
Chest, 104 (1993), pp. 0.997-1.002
[5.]
E.C. Patz, V.J. Lowe, J.M. Hoffman.
Focal pulmonary abnormalities: evaluation with F-18 Fluorodeoxyglucose PET scanning.
Radiology, 188 (1993), pp. 487-490
[6.]
N.A. Dewan, S.D. Reeb, N.C. Gupta.
PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
Chest, 108 (1995), pp. 441-446
[7.]
T. Bury, A. Dowlati, P. Paulus, J.L. Corhay, T. Benoit, J.M. Kayembe, et al.
Evaluation of the solitary pulmonary nodule by positron emission tomography imaging.
Eur Resp J, 9 (1996), pp. 410-414
[8.]
F.G. Duhaylongsod, V.J. Lowe, E.F. Patz Jr., A.L. Vaughn, R.E. Coleman, W.G. Wolfe.
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography.
Ann Thorac Surg, 60 (1995), pp. 1.348-1.352
[9.]
V.J. Lowe, D.M. Delong, J.M. Hoffman, R.E. Coleman.
Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
J Nucl Med, 36 (1995), pp. 883-887
[10.]
H. Minn, K.R. Zasadny, L.E. Quint.
Lung cancer reproducibility of quantitative measurements for evaluating 2-(F-18)-fluoro-2deoxy-D-glucose uptake at PET.
Radiology, 196 (1995), pp. 167-173
[11.]
S.U. Berlangien, A.M. Scott, S. Knight.
Mediastinal lymph node staging in non-small cell lung carcinoma: comparison of F-18 FDG positron emission tomography with surgical pathology.
Eur J Nucl Med, 21 (1994), pp. S62
[12.]
M. Sasaki, Y. Ichiya, Y. Kuwabawa, Y. Akashi, T. Yoshida, T. Fukumura, et al.
The usefulness of FDG positrón emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.
Eur J Nucl Med, 23 (1996), pp. 741-747
[13.]
E.F. Patz Jr., V.J. Lowe, P.C. Goodman, J. Hemdon.
Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.
Chest, 108 (1995), pp. 1.617-1.621
[14.]
P.E. Valk, T.R. Pounds, D.M. Hopkins, R. Myers, M. Haseman, C.L. Lutrin.
Staging lung cancer by PET imaging.
Ann Thorac Surg, 60 (1995), pp. 1.573-1.582
[15.]
H.C. Steinert, M. Hauser, F. Allemann, H. Engel, T. Berthold, G.K. Von Schulthess, et al.
Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
Radiology, 202 (1997), pp. 444-446
[16.]
P. Lewis, S. Griffin, P. Marsden, T. Gee, T. Nunan, M. Malsey, et al.
Whole-body 18F-fluorodeoxiglucose positron emission tomography in preoperative evaluation of lung cancer.
Lancet, 344 (1994), pp. 1.265-1.266
[17.]
T. Bury, A. Dowlati, P. Paulus, T. Hustinx, M. Radermecker, P. Rigo.
Staging of non small cell lung cancer by whole-body 18FDG-PET.
Eur J Nucl Med, 23 (1996), pp. 204-206
[18.]
T. Bury, A. Dowlati, P. Paulus, A. Lamproye, P. Rigo, M. Radermecker.
Positron emission tomography versus computed tomography in the staging of mediastinal non-small cell lung cancer [resumen].
Eur Resp J, 22 (1995), pp. 846
[19.]
R.L. Whahl, L.E. Quint, R.L. Greenough, C.R. Meyer, R.I. White, M.B. Orringer.
Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Radiology, 191 (1994), pp. 371-377
[20.]
M.V. Knopp, H. Bischoff, A. Rima.
Clinical utility of positron emission tomography with FDG for chemotherapy response monitoring. A correlative study of patients with small-cell lung cancer.
J Nucl Med, 35 (1994), pp. 75
[21.]
F.G. Duhaylongsod, V.J. Lowe, E.F. Patz.
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET).
J Thorac Cardiovasc Surg, 110 (1995), pp. 139-140
[22.]
A. Frank, D. Lefkowitz, S. Jaeger.
Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Int J Radiot Oncol Biol Phys, 32 (1995), pp. 1.495-1.512
[23.]
T. Inoue, E. King, R. Komaki.
Detecting recurrent or residual lung cancer with FDG-PET.
J Nucl Med, 36 (1995), pp. 788-793
[24.]
H.M. Wu, S.C. Huong, Y. Choi, C.K. Hoh, R.A. Hawkins.
A modeling method to improve quantitation of fluorodeoxiglucose uptake in heterogeneous tumor tissue.
J Nucl Med, 36 (1995), pp. 297-306
[25.]
C.K. Hoh, C. Schiepers, M.A. Seltzer, S.S. Gambhir, D.H.S. Silverman, J. Czernin, et al.
PET in oncology: will it replace the other modalities?.
Semin Nucl Med, 27 (1997), pp. 94-106
Estudio parcialmente financiado por la Universidad Complutense de Madrid (Beca de Investigación 1996–1997).
Copyright © 1997. Sociedad Española de Neumología y Cirugía Torácica
